-

$undefined

N/A

(N/A)

Pyxis Oncology NasdaqGS:PYXS Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Location: 321 Harrison Avenue, Boston, MA, 02118, United States | Website: https://www.pyxisoncology.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-8.155M

Cash

105.4M

Avg Qtr Burn

-14.87M

Short % of Float

15.79%

Insider Ownership

22.46%

Institutional Own.

38.31%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Micvotabart pelidotin (MICVO, formerly PYX-201) Details Cancer, r/m Head and neck squamous cell carcinoma (HNSCC) EGFRi & PD-1 Experienced	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Micvotabart pelidotin (MICVO, formerly PYX-201) Details Cancer, r/m Head and neck squamous cell carcinoma (HNSCC) 2/3L Platinum & PD-1 Experienced	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Micvotabart pelidotin (MICVO, formerly PYX-201) Details Cancer, r/m Head and neck squamous cell carcinoma (HNSCC) 1/2L+	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Micvotabart pelidotin (MICVO, formerly PYX-201) + Pembrolizumab Details Solid tumor/s (various)	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Micvotabart pelidotin (MICVO, formerly PYX-201) Details Head and neck cancer, Breast cancer, Thyroid cancer, Lung cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PYX-106 Details Colorectal cancer , Kidney cancer, Bladder cancer, Cholangiocarcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.